| |
Severe (N=108)
|
Non-severe (N=298)
|
|---|
|
Regiona
|
|
Single region
|
68 (63.0%)
|
226 (75.8%)
|
|
Multi-region
|
21 (19.4%)
|
23 (7.7%)
|
|
Unknown
|
19 (17.6%)
|
49 (16.4%)
|
|
Countriesa
|
|
Canada
|
4 (3.7%)
|
19 (6.4%)
|
|
USA
|
35 (32.4%)
|
58 (19.5%)
|
|
France
|
10 (9.3%)
|
31 (10.4%)
|
|
Germany
|
8 (7.4%)
|
9 (3.0%)
|
|
Italy
|
5 (4.6%)
|
16 (5.4%)
|
|
Russia
|
9 (8.3%)
|
11 (3.7%)
|
|
Spain
|
11 (10.2%)
|
18 (6.0%)
|
|
UK
|
11 (10.2%)
|
13 (4.4%)
|
|
China
|
3 (2.8%)
|
9 (3.0%)
|
|
Japan
|
6 (5.6%)
|
6 (2.0%)
|
|
Brazil
|
14 (13.0%)
|
22 (7.4%)
|
|
Others
|
40 (37.0%)
|
124 (41.6%)
|
|
Number of endpoints
|
|
Mean (SD)
|
12.8 (10.7)
|
9.0 (7.7)
|
|
Median (IQR)
|
9 (6, 16.3)
|
7 (4, 12)
|
|
Number of primary endpointsa
|
|
1
|
86 (79.6%)
|
216 (72.5%)
|
|
2
|
13 (12.0%)
|
42 (14.1%)
|
|
≥3
|
9 (8.3%)
|
40 (13.4%)
|
|
Number of armsa
|
|
1b
|
18 (16.7%)
|
63 (21.1%)
|
|
2b
|
64 (59.3%)
|
177 (59.4%)
|
|
≥3b
|
26 (24.1%)
|
58 (19.5%)
|
|
Sample size (trials with 1 armb)
|
|
Mean (SD)
|
367.8 (378.2)
|
396.3 (553.2)
|
|
Median (IQR)
|
205 (100, 462)
|
200 (100, 466)
|
|
Sample size (trials with 2 armsb)
|
|
Mean (SD)
|
519.2 (652.9)
|
576.9 (831.3)
|
|
Median (IQR)
|
372 (230, 600)
|
300 (108, 690)
|
|
Sample size (trials with ≥3 armsb)
|
|
Mean (SD)
|
806.6 (787.3)
|
1149.1 (2433.9)
|
|
Median (IQR)
|
475 (200, 1116)
|
305 (200, 700)
|
- aFrequency (percentage); bA single drug with multiple doses that was placed under the same “Arm” in interventions was considered as one arm
- SD standard deviation, IQR interquartile range
